

Technical University of Denmark



The future of antiviral immunotoxins

Spiess, K.; Høy Jakobsen, Mette; Kledal, Thomas N; Rosenkilde, Mette M.

Published in:
Journal of Leukocyte Biology

Link to article, DOI:
[10.1189/jlb.2mr1015-468r](https://doi.org/10.1189/jlb.2mr1015-468r)

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
Spiess, K., Høy Jakobsen, M., Kledal, T. N., & Rosenkilde, M. M. (2016). The future of antiviral immunotoxins. *Journal of Leukocyte Biology*, 99(6), 911-925. DOI: 10.1189/jlb.2mr1015-468r

DTU Library

Technical Information Center of Denmark

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

The future of antiviral immunotoxins

Katja Spiess,* Mette Høy Jakobsen,* Thomas N. Kledal,[†] and Mette M. Rosenkilde*¹

*Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Science, University of Copenhagen, Denmark; and [†]Section for Virology, Veterinary Institute, The Danish Technical University, Denmark

RECEIVED OCTOBER 12, 2015; REVISED DECEMBER 2, 2015; ACCEPTED DECEMBER 3, 2015. DOI: 10.1189/jlb.2MR1015-468R

ABSTRACT

There is a constant need for new therapeutic interventions in a wide range of infectious diseases. Over the past few years, the immunotoxins have entered the stage as promising antiviral treatments. Immunotoxins have been extensively explored in cancer treatment and have achieved FDA approval in several cases. Indeed, the design of new anticancer immunotoxins is a rapidly developing field. However, at present, several immunotoxins have been developed targeting a variety of different viruses with high specificity and efficacy. Rather than blocking a viral or cellular pathway needed for virus replication and dissemination, immunotoxins exert their effect by killing and eradicating the pool of infected cells. By targeting a virus-encoded target molecule, it is possible to obtain superior selectivity and drastically limit the side effects, which is an immunotoxin-related challenge that has hindered the success of immunotoxins in cancer treatment. Therefore, it seems beneficial to use immunotoxins for the treatment of virus infections. One recent example showed that targeting of virus-encoded 7 transmembrane (7TM) receptors by immunotoxins could be a future strategy for designing ultraspecific antiviral treatment, ensuring efficient internalization and hence efficient eradication of the pool of infected cells, both *in vitro* and *in vivo*. In this review, we provide an overview of the mechanisms of action of immunotoxins and highlight the advantages of immunotoxins as future anti-viral therapies. *J. Leukoc. Biol.* 99: 000-000; 2016.

Introduction

Despite modern prevention and treatment strategies, viral infections and subsequent diseases remain a major health concern with devastating consequences associated with morbidity, mortality, and burdensome economic consequences. Currently, licensed drugs for the treatment of viral infections have several drawbacks, including toxicity and emergence of drug resistance. Hence, new and improved antiviral therapies with novel modes of

action are urgently needed, and use of antiviral immunotoxins as “smart bombs” provide 1 such option.

Immunotoxins are fusion molecules that consist of a targeting molecule conjugated to a toxin molecule. The targeting molecule can be either antibody based, such as a mAb and a genetically engineered single-/double-chain antibody fragment or a receptor ligand, such as a growth factor or cytokine that targets specific cell surface receptors (Fig. 1) [1, 2]. The targeting molecule can be fused to a range of toxins, such as bacterial, plant, or fungal toxins, or to human apoptotic proteins. Although the toxin ensures efficient killing of the diseased or infected target cell, the targeting moiety ensures selectivity (i.e., that the killing moiety is directed to the diseased cells only). The selectivity must be accompanied by efficient internalization of the immunotoxin. Thus, selection of the appropriate immunotoxin target not only relies on the target expression profile, but must also take target internalization into account [3]. Furthermore, immunotoxins are highly immunogenic molecules and may rapidly elicit an immune response when administered to humans. Improvement in design of the immunotoxins is therefore warranted (e.g., identification and silencing of human T cell epitopes [4]) to overcome resistance and to achieve low immunogenicity for repeated treatment cycles.


Mostly, but not exclusively, immunotoxins are purpose-built to kill cancer cells. Thus, the identification of numerous unique cancer targets in recent years has led to the development of various malignancy-directed immunotoxins, with successful approval by the FDA (Table 1). The early immunotoxin denileukin difitox (Ontak, Eisai, Inc., Woodcliff Lake, NJ, USA) with the targeting molecule IL-2 fused to the C terminus of DT received accelerated approval for the treatment of CD-25-positive cutaneous T cell lymphoma in 1999 and received regular approval in 2008 [5–8]. A subclass of immunotoxins, known as immunoconjugates, contains an antibody for specific antigen targeting. The antibody is coupled to a variety of effector molecules by cleavable or uncleavable linkers that ensure optimal delivery of the effector molecule into the cell (Fig. 1). Immunoconjugates can be both highly specific and effective and with minimal toxicity if they are optimally designed. Therefore, certain immunoconjugates are considered among the most

Abbreviations: 7TM = 7 transmembrane, ACD = antibody drug conjugate, BLT = bone marrow-liver-thymus, CD = Castleman's disease, DT = diphtheria toxin, Env = envelope, FDA = U.S. Food and Drug Administration, FTP = fusion toxin protein, gp = glycoprotein, GPCR = G protein-coupled receptor, HCMV = human CMV, HCV = hepatitis C virus, KSHV = Kaposi sarcoma-associated herpes virus, MCD = multicentric Castleman's disease,

(continued on next page)

1. Correspondence: Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen 2200, Denmark. E-mail: rosenkilde@sund.ku.dk

Figure 1. Structure of immunotoxins and immunoconjugates. Immunotoxins are composed of a target molecule, that can be in the form of an antibody, a growth factor, or a cytokine that directs the immunotoxin to its specific molecular target, which is cell or virus derived. The target molecule and the therapeutic can be directly fused to each other or connected by a linker molecule. The therapeutic consists of a toxin molecule derived from plants, bacteria, or fungi or an apoptotic protein that will kill the targeted cell when internalized. Immunoconjugates always have an antibody as the target molecule, which is specific to cell- or virus-derived targets. The target molecule is combined to the therapeutic by a linker, and the therapeutic is a drug substance, a radio ligand, or a toxin.



promising anticancer therapies in the clinic [9]. There are 3 classes of immunoconjugates, based on the mechanism of action of the therapeutic agent conjugated to the antibody. The first class includes a pharmacological drug-like substance; members of this class are also known as ADCs. The second class consists of radionucleotides and the third class, of catalytic toxins (Fig. 1) [9]. The 2 most well-described immunoconjugates to date belong to class 1: brentuximab vedotin (targeting CD30) and trastuzumab emtansine (targeting HER2), approved by the FDA for the treatment of certain lymphomas and breast cancer, respectively [10, 11]. Radionucleotide immunoconjugates (class 2) (e.g., ibritumomab tiuxetan and iodine tositumomab) have shown clinical efficacy in the treatment of hematologic malignancies, but have failed in solid-tumor management [12–14]. Several immunoconjugates that involve a catalytic toxin (class 3) show promising results and are under clinical evaluation (phase I–III trials) and preclinical trials [9, 15]. Table 1 provides an overview of immunotoxins for treatment of cancers. Given the impressive progress in anticancer immunotoxin development, in particular regarding efficacy and safety, there is great potential of this technique for other clinical indications, such as infectious diseases, where pathogen-encoded targets provide superior specificity as compared to up-regulated endogenous target molecules in cancers. In the this review we focus on

(continued from previous page)

MCMV = murine CMV, PCV = Pichinde virus, pAb = polyclonal antibody, PE = *Pseudomonas* exotoxin A, PEL = primary effusion lymphoma, PTLD = posttransplant lymphoproliferative disease, vGPCR = viral GPCR, VHH = heavy-chain-only antibody, WT = wild-type

immunotoxins for the treatment of virus infections. At present, all antiviral immunotoxins are antibody based, yet 1 exemption recently entered the stage by presentation of the first antiviral immunotoxin targeting a virus-encoded 7TM GPCR denoted US28—not by an antibody, but by refinement of a chemotactic cytokine (chemokine) for optimal binding to US28 [16]. We discuss existing antiviral immunotoxins, novel viral targets for immunotoxins with main focus on virus-encoded 7TM GPCRs, and perspectives on the future of immunotoxin-based antiviral therapy.

IMMUNOTOXINS AS NOVEL ANTIVIRAL THERAPEUTICS

Today's antiviral therapies intervene in the infection cycle of the virus by primarily targeting virus entry, intracellular virus replication, virus particle formation, and cell exit or by modulating cellular immune defense systems [17]. Immunotoxins as antiviral therapeutics are relatively underexploited, but are potentially useful, as these molecules can interfere with virus replication at the same time as killing virus-infected cells [16, 18]. The greatest advantage, in comparison with anticancer immunotoxins, is that the target molecule often is encoded by the virus, thereby preventing side effects encountered by killing of cells expressing low levels of the targeted human molecule (Table 2). In addition, interference with the protein synthesis within infected eukaryotic cells blocks virus dissemination and may eliminate the reservoirs in latently infected cells from which the virus reactivates [19].

TABLE 1. Characteristics and developmental state of immunotoxins used for cancer treatment. The immunotoxins are listed in alphabetic order. Molecular targets of the immunotoxins are shown in bold. Immunotoxins described in the text are shown on grey background.

Immunotoxin	Targeting moiety: molecular target	Toxin moiety	Type of cancer	Developmental stage	References
260F9 Mab-rRA	Anti-M _r 55,000 murine mAb (260F9): M_r 55,000 antigen	RicA	Breast cancer	Terminated in phase I (1989)	[86, 87]
454A12-rRA	Anti-human TFR mAb (454A12): TFR	RicA	Ventricular cerebrospinal fluid cancer	Phase I	[88, 89]
A-dmDT390-bisFv	Anti-CD3 with addition of an extra sFv domain: CD3	DT	CTCL	Phase I	[90, 91]
Ado-trastuzumab emtansine (Kadcyla)	Anti-HER2 mAb (trastuzumab): ErbB2	DM1 ^a	Breast cancer	FDA approved (22.02.2013)	[11, 92–100]
Anti-B4-bRicin	Anti-CD19 mAb: CD19	Blocked Ricin	B-cell non-Hodgkin lymphoma	Terminated in phase III (2011)	[101–106]
Anti-MY9-bRicin	Anti-CD33 mAb (MY9): CD33	RicB	AML	Terminated in phase I (1998)	[107];
B43-PAP	Anti-CD19 mAb (B43): CD19	PAP	ALL	Phase I	[108, 109]
Ber-H2-Sap6 ^c	Anti-CD30 mAb (Ber-H2): CD30	Saporin 6	Hodgkin disease	Phase I	[110–112]
BL22 (RFB4(dsFv) PE38 or CAT-3888)	Disulfide-linked V _H and V _L chains of Anti-CD22 Fv fragment (RFB4): CD22	PE-38	B-cell malignancy	Phase II trials completed, superseded by moxetumomab pasudotox	[113–117]
Brentuximab vedotin (Adcetris)	Mouse-human chimeric IgG1 anti-CD30 mAb: CD30	MMAE ^a	Hodgkin lymphoma; anaplastic large cell lymphoma	Accelerated FDA approval (10-19-2011)	[10, 118–123]
Cintredekin besudotox	IL-13: IL-13Rα2	PE truncated form, PE38QQQR	Malignant glioma	Terminated in phase III (2010)	[124–127]
DA7	Mouse anti-CD7 human mAb: CD7	dgA	T-cell non-Hodgkin lymphoma	Phase I	[128, 129]
DAB ₄₈₆ IL-2 ^c	IL2: CD25	DAB ₄₈₆	Hematologic cancer	Phase I/II	[130–134]
Denileukin diftitox (ONTAK) ^c	IL2: CD25	DAB ₃₈₉	CTCL	FDA approved	[7, 135–141]
DT390-GM-CSF and DT388-GM-CSF	GM-CSF: GM-CSFR	DT390	AML	Phase I	[142–144].
DT388-IL3	IL-3: IL-3R	DT388	AML	Phase I/II ^b	[145, 146]
erb-38	Disulfide stabilized Fv portion of mAb e23 dsFv: ErbB2	PE38	Breast cancer	Phase I	[147–149]
Gemtuzumab ozogamicin (Mylotarg)	Anti CD33 mAb (hP67.6): CD33	Calicheamicin	AML	FDA approved (05-17-2000) but later withdrawn (10-15-2010)	[150] ^b , [151–154]
H65-RTA	Anti-CD5 mAb (H65): CD5	RicA	CTCL	Phase I/II	[155, 156]
HD37-dgA	Anti-CD19 mAb (HD37): CD19	dgA	B-non Hodgkin lymphoma	Phase I	[157, 158]
HUM-195/rGEL	Anti-CD33 humanized mAb (M195): CD33	rGel	Refractory myeloid leukemias	Phase I	[159–161]

(continued on next page)

TABLE 1. (continued)

Immunotoxin	Targeting moiety: molecular target	Toxin moiety	Type of cancer	Developmental stage	References
IL4-PE	Circularly permuted IL-4	PE38KDEL	Malignant glioma	Phase I /II	[162–165]
Ki-4.dgA	Anti-CD30 mAb: CD30	dgA	Hodgkin's disease	Phase I/II	[166, 167]
B3(LysPE40) and LMB-1 (B3(LysPE38))	Anti-Le ^Y mAb (B3): Lewis Y	LysPE-40 and LysPE-38	Breast cancer and colon cancer	Phase II	[168–170]
Anti-TAC(Fv)PE40 and LMB-2 (anti-TAC (scFv)PE38)	Anti-CD25 Fv portion (anti-tac): CD25	PE40	CD25 ⁺ T- and B- cell malignancies	Phase I, recruiting for a phase II study	[171–173].
LMB-7 (B3(Fv)–PE38)	Anti-Le ^Y mAb single chain Fv fragment [B3 (Fv)]: Lewis Y	PE-38KDEL	Neoplastic meningitis	Terminated in phase I (2000) ^b	[174]
LMB-9 (B3(dsFv)–PE38)	Stable disulphide version of B3(Fv) [B3(dsFv)]: Lewis Y	PE-38	Bladder, lung, breast, GI-tract and pancreatic cancers	Terminated in phase I (2003) ^b	[175]
Moxetumomab pasudotox	RFB4 with point mutations Ser100Thr, Ser100aHis and Tyr100bTrp in heavy-chain CDR3: CD22	PE-38	B cell malignancies	Phase I, recruiting for a phase II study phase I ^b	[176, 177]
MR1-1	Anti-EGFRvIII mAb scFv fragment: EGFR vIII	PE38KDEL	Glioblastoma multiforme	Phase I ^b	[178]
N901-bR	Anti-CD56 mAb: CD56	Blocked ricin	Small cell lung cancer	Terminated in phase II (2002)	[179–181]
OVB3-PE	Anti-ovarian cancer cell mAb (OVB-3): unknown antigen on ovarian cancer cells	PE	Ovarian cancer	Terminated in phase I (1991)	[182, 183]
RFB4-dgA	Anti-CD22 murine mAb (RFB): CD22	dgA	B-non Hodgkin lymphoma,	Phase I	[184–187]
RFB4-Fab-dgA	FAB' fragment of RFB: CD22	dgA	B-non Hodgkin lymphoma	Phase I	[188, 189]
RFT5-dgA ^c	Anti-CD25 Ab: CD25	dgA	Hodgkin's disease	Phase I/II	[190–194]
ScFv(FRP5)-ETA	N-terminal single-chain Ab fragment (scFv) specific to ErbB2: ErbB2	PE	Breast, head, prostate and neck cancers.	Phase I	[195, 196]
SGN-10	Linked heavy- and light-chain variable regions of murine mAb BR96 (BR96 (sFv)): Lewis Y	PE40	Le ^Y -positive non hematological metastatic carcinomas	Phase I	[197, 198]
SS1P	Anti-mesothelin single-chain Fv Ab: Mesothelin	PE-38	Mesothelioma, ovarian and pancreatic cancers	Phase I, recruiting for a phase II study	[199–202]
T101-ricin A chain	Anti-65 kD GP mAb (T101): 65 kD GP	RicA	CLL	Terminated in phase I (1988)	[203, 204]
TF-CRM107	Transferrin-C: TFR	DT (with mutations Leu390Phe Ser525Phe in the B chain)	Malignant glioma	Phase III study completed in 2008 ^b	[205–208]

(continued on next page)

TABLE 1. (continued)

Immunotoxin	Targeting moiety: molecular target	Toxin moiety	Type of cancer	Developmental stage	References
TGF α -TP40	TGF- α : EGFR	PE-40	Bladder cancer	Phase I	[209, 210]
TGF α -TP38	TGF- α : EGFR	PE-38	Malignant glioma	Phase II	[211–214]
XomaZyme-791	Murine anti-colon carcinoma mAb (791T/36): M_r 72,000 antigens on colon carcinoma cells.	RicA	Colon cancer	Phase I	[215, 216]
XomaZyme-MEL (or XMMME-001-RTA)	Murine anti-melanoma mAb: melanoma antigens with a molecular weight of 220,000 and over 500,000	RicA	Melanoma	Phase II	[217–219]

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; DAB, modified diphtheria toxin; DAB389, the first 389 amino acids of DT; CLL, chronic lymphocytic leukemia; CTCL, cutaneous T-cell lymphoma; dgA, deglycosylated ricin-A-chain; DM1, derivative of maytansine 1; DT, diphtheria toxin; EGFR, epidermal growth factor receptor; FCRL-5, Fc receptor-like protein 5; GI, gastrointestinal; GM-CSFR, Granulocyte-macrophage colony-stimulating factor; HER, human epidermal growth factor receptor; kD, kilodalton; MC, mixed cryoglobulinemia; MMAE, Dolastatin 10 analog monomethyl auristatin e; MZ, marginal zone; PAP, pokeweed antiviral protein; PE38, genetically engineered deletion of amino acids 253-334 and 381-613 of PE; PE38KDEL, truncated form of PE where the amino acids KDEL is added in the C terminal region to increase toxicity; PE40, deletion of domain Ia of PE; rGEL, recombinant gelonin; RicA, ricin A chain; RicB, ricin B chain; TFR, transferrin receptor; VH, heavy chain domain of variable Ab region; VL, light chain domain of variable Ab region. ^aOnly immunotoxins based on non-classical (not bacterial, plant or fungal derived) toxins that are FDA approved are included in the table. ^bUnpublished data. ^cImmunotoxins tested as both cancer and viral treatment.

Antibody-based immunotoxins for virus targeting

Immunotoxins have been developed against a variety of viruses, including small single-stranded RNA viruses, such as HIV, PCV, and HCV, and larger DNA viruses, such as herpesviruses. (Table 2 provides a comprehensive overview of antiviral immunotoxins). In this review we focus on the most well-investigated immunotoxins against HIV and herpesviruses.

Antibody-based immunotoxins

Antibody-based immunotoxins were assessed as a monotherapy for HIV infection soon after the identification of HIV as the causative agent of AIDS [20–23], but were found to be ineffective [24–26]. At present, immunotoxins are under consideration for incorporation into HIV eradication protocols in combination therapy [18, 24, 27]. Today's antiretroviral treatment provides a lifesaving and effective control of HIV infections [28], as it promotes dramatic reductions in viral load in blood and lymphoid tissues and is accompanied by significant recovery of CD4⁺ T-lymphocyte counts and immune system function [29]. However, infected cell reservoirs and low-level replication of HIV persist during years of suppressive antiretroviral treatment, leading to viral rebound upon cessation of treatment [29]. Therefore, adherence to daily treatment is essential, but with the potential consequence that drug resistance of viral variants may emerge. Therefore, strategies for HIV eradication therapies have been pursued [18, 30, 31], and immunotoxins have been tested for HIV eradication in combination with an antiretroviral therapy. HIV cell entry is facilitated by the sequential interaction of the viral Env gp120 with CD4 on the surface of the cell [32]. Therefore, immunotoxins consisting of antibodies binding to

gp120 linked to the truncated form of PE have been developed. The 3B3(Fv)-PE38 (hereafter, 3B3-PE) is an improved version of the CD4(178)-PE40 (hereafter, CD4-PE) immunotoxin [26, 29]. Both immunotoxins display highly potent and specific cytotoxic actions in vitro against replication of HIV in PBMCs and monocyte-derived macrophages [33, 34]. This effect is particularly noteworthy in view of the extremely low levels of surface Env expression in macrophages and the postulated role of macrophages in HIV persistence during antiretroviral treatment [34]. A thymus-liver SCID-hu mouse was used to examine the ability of both immunotoxins in combination with antiretroviral drugs to treat HIV infections in vivo. HIV tropism is confined to human tissue that is capable of supporting a productive infection of the virus. Thus, to establish HIV infection in a mouse model, SCID mice underwent implantation of human fetal thymus and liver under the mouse kidney capsule [35]. Both immunotoxins strikingly improved traditional anti-HIV treatment, but did not eradicate the infection. Recently, 3B3-PE has been tested further in a BLT humanized mouse model, which has been validated in the study of HIV persistence [18]. The process of bioengineering BLT mice results in systemic dissemination of human hematopoietic cells through the animal [36]. After effects of HIV infection on the BLT mouse human immune system were observed (e.g., CD4⁺ T cell depletion and immune activation), antiretroviral therapy was established, and 3B3-PE was incorporated into the therapeutic regimen. 3B3-PE significantly improved the anti-HIV treatment, by profoundly depleting productively infected cells systemically, but did not eliminate the virus [18].

The tested immunotoxins can limit the size of the HIV reservoir, but cannot eradicate HIV in combination with the

TABLE 2. Characteristics and developmental state of immunotoxins used for viral treatment. The immunotoxins are listed in alphabetic order. Molecular targets of the immunotoxins are shown in bold and further in italics if the target is virally expressed. Immunotoxins described in the text are shown on grey background.

Immunotoxin	Targeting moiety: Molecular target (<i>viral</i> or human)	Toxin moiety	Type of infection	References
0.5β-RAC and 0.5β-PE	mAb 0.5β: <i>gp120</i>	RicA/PE	HIV	[220]
3B3 (Fv)-PE38	3B3 scFv Ab: <i>gp120</i>	PE38	HIV	[221]
25-D1.16 Fab/pOV8-K ^b	Heavy and light chains of TCR-like Ab 25-D1.16 Fab fragment: pOV8 (SIINFEKL) in association with H-2K^b class I MHC (pOV8-K^b)	PE38	Rabies virus	[222]
41.1-Ricin A	Anti-gp41 human mAb 41.1: <i>aa 579–603 of gp41</i>	dgA	HIV	[223]
907-RAC	Anti-gp120 mAb 907: <i>aa 313–324 of gp120</i>	RicA	HIV	[224]
924-Ricin A	Anti-gp120 mAb 924: <i>aa 313–324 of gp120</i>	RicA	HIV	[223]
2014-PE38	Anti-KSHV K8.1A mAb (4C3): <i>gpK8.1A viral glycoprotein</i>	PE38	KSHV ⁺ KSHV-associated cancers	[42]
Anti-CD45RO IT	Anti-CD45RO Ab: CD45RO	dgA	HIV	[225]
Anti-gp41-dgA (98-6-dgA + 50-69-dgA)	Anti-gp41 mAb: <i>gp41</i>	dgA	HIV	[226]
Anti-gp160 IT	Anti-gp160 polyclonal Ab: <i>gp160</i>	dgA	HIV	[223]
BAT123-PAP	BAT 123 mAb: <i>aa 307–317 of the PND region on gp120</i>	PAP	HIV	[227]
Ber-H2-Sap6 ^c	Anti-CD30: CD30	Saporin6	CD30 ⁺ EBV ⁺ B-cell tumors	[228]
CD4(178)PE40	First 178 amino acids of CD4 [rsCD4(178)]: gp120 binding domain of CD4	PE40	HIV	[230, 231, 26] Terminated in phase III (1994)
CytG-gelonin	Anti-HCMV polyclonal human IgG: <i>HCMV infected cells</i>	Gelonin	HCMV	[51]
CytG-gelonin	Anti-MCMV polyclonal IgG: <i>MCMV-infected cells</i>	Gelonin	MCMV	[51]
DAB389CD4	rsCD4(178): gp120 binding domain of CD4	DAB389	HIV	[231]
DAB ₄₈₆ IL-2 ^c	rIL-2: CD25	DAB486	HIV	[130, 232]
DAB ₃₈₉ IL-2 ^c	rIL-2: CD25	DAB389	HIV	[135, 233]
F49A-FTP	CX ₃ CL1 with a single-point mutation (Phe49Ala): <i>US28</i>	PE	HCMV ⁺ HCMV-associated glioblastoma	[16]
F58-RAC	mAb F58: <i>aa 309–317 of gp120</i>	RicA	HIV	[234]
G3.519-PAP-S	mAb G3.519: gp120 binding domain of CD4	PAP-S	HIV	[227]
HB5-gelonin	Anti-C3d Mab (HB5): EBV/C3d receptor	Gelonin	EBV associated malignancy	[235]
HMS-dgA, C34-dgA and D5-dgA	Anti-MCMV monoclonal IgG: <i>MCMV infected cells</i>	dgA	MCMV	[52]
HRS-gelonin	Anti-PCV mAb (HRS): <i>PCV antigen</i>	Gelonin	PCV	[236]
PAP-anti-CD4	Anti-CD4 mAb: gp120 binding domain of CD4 Anti-CD5 mAb: CD5 Anti CD7 mAb: CD7	PAP	HIV	[237]
R33ExoA	Anti-viral surface gp D (R33) variable domains of VHH: <i>Viral surface gp D</i>	PE	HSV-2	[19]
rCD4-dgA	rsCD4(178): gp120 binding domain of CD4	dgA	HIV	[238]

(continued on next page)

TABLE 2. (continued)

Immunotoxin	Targeting moiety: Molecular target (<i>viral</i> or human)	Toxin moiety	Type of infection	References
RFT5-dgA ^c	Anti-CD25 mAb (RFT5): CD25	dgA	HIV	[239, 240]
UCHT1-DT	Anti-CD3 mAb: CD3	DT	HIV	[241]
YC15-PE38	Single-chain variable region fragment anti-KSHV gH mAb: KSHV gH	PE38	KSHV + KSHV associated MCD	[41]

The immunotoxins are listed in alphabetical order. Molecular targets of the immunotoxins are shown in bold and further in italics if the target is virally expressed. Immunotoxins described in the text are shown on gray background. AML=acute myeloid leukemia; DAB=modified diphtheria toxin; DAB₃₈₉=the first 389 amino acids of DT; CDR=complementarity-determining regions; CLL=chronic lymphocytic leukemia; CTCL=cutaneous T-cell lymphoma; dgA=deglycosylated ricin-A-chain; DM1=derivative of maytansine 1; EGFR=epidermal growth factor receptor; FCRL-5=Fc receptor-like protein 5; gH=glycoprotein H; GI=gastrointestinal; GM-CSFR=granulocyte-macrophage colony-stimulating factor; HER=human epidermal growth factor receptor; MC=mixed cryoglobulinemia; MMAE=dolastatin 10 analog monomethyl auristatin; MZ=marginal zone; PAP=pokeweed antiviral protein; PE38=genetically engineered deletion of aa 253–334 and 381–613 of PE; PE38KDEL=truncated form of PE where the amino acids KDEL is added in the C terminal region to increase toxicity; PE40=deletion of domain Ia of PE; *PNAS=Proc. Natl. Acad. Sci. USA*; rGEL=recombinant gelonin; RicA=ricin A chain; RicB=ricin B chain; TFR=transferrin receptor; V_H=heavy chain domain of variable Ab region; V_L=light chain domain of variable Ab region. ^aOnly immunotoxins based on nonclassic (not bacteria-, plant-, or fungus-derived) toxins that are FDA approved are included in the table. ^bUnpublished data. ^cImmunotoxins tested as both cancer and viral treatments.

antiretroviral therapy. However, based on the results, alternative immunotoxins with different effector molecules and targeting moieties (Table 2) could be successful components of an effective HIV eradication therapy.

Antibody-based immunotoxins targeting herpesviruses

Antibody-based immunotoxins targeting herpesviruses have shown promising results in several cases, as discussed in detail below.

Antibody-based immunotoxins against KSHV. KSHV (also known as HHV-8) is an oncogenic virus that has been characterized as the etiologic agent in the onset and development of KS, PEL, and MCD [37, 38]. Like other herpesviruses, KSHV possesses 2 distinct transcriptional programs: latency and lytic replication [39]. In the latent phase, viral genomes are maintained silent within the infected cells, and in the lytic phase, all lytic viral genes are expressed in a tightly regulated cascade, after which the progeny virus is assembled and released from the infected cell. Two immunotoxins have been developed for selective killing of lytically infected cells: YC15-PE38 and 2014-PE38 [40, 41]. They both consist of a single chain Fv mAb targeting KSHV lytic gps linked to the truncated form of PE (PE38). The targeted gps are expressed on KSHV particles to facilitate virus entry, and consequently, the spread of the infection in the human host. YC15-PE38 binds to the KSHV gpH [40] and the antibody fragment of 2014-PE38 is against gpK8.1A [42]. Both immunotoxins have been shown to inhibit the production of infectious KSHV particles and specifically to kill KSHV-infected cells in a dose-dependent fashion in vitro. In particular, 2014-PE38 was observed to be efficient, even under conditions of very low gpK8.1A expression, and has therefore been discussed as a potential treatment for MCD, as this cancer is mostly associated with the lytic phase of the viral life cycle, when gpK8.1A is expressed [41].

Antibody-based immunotoxin against HSV-2. HSV-2 is one of the most prevalent sexually transmitted infections [43]. In addition to recurrent genital ulcers, HSV-2 causes neonatal herpes and is associated with a 3-fold increased risk for HIV

acquisition [44]. Structurally altered antibodies produced by the camelid family are currently exploited for the treatment of HSV-2. Members of this family (camels, llamas, and alpacas) can produce antibodies that lack light chain and CH1 domain, also denoted VHHs [45]. VHHs demonstrate the same antigen-binding capability as full-length antibodies and are purified as monomeric domains. They demonstrate remarkable stability in a wide range of denaturing, temperature, and pH conditions. These properties of VHH have been exploited in the development of an immunotoxin for intravaginal use in the treatment of HSV-2 [46].

Using a phage display library constructed from a llama immunized with a recombinant HSV-2-encoded gpD, a single-domain antibody VHH, R33, was identified with specific binding to the viral cell surface gpD. R33 did not demonstrate any HSV-2 neutralization. However, fusion of R33 to the cytotoxic domain of PE yielded an immunotoxin (R33ExoA) which, unlike existing antivirals targeting HSV-2, was highly efficient in killing virus-infected cells in vitro [46]. R33ExoA is the first immunotoxin designed for targeting a virus at a mucosal site of infection, but to be considered for anti-HSV-2 therapy, its efficacy under exceptional conditions in vivo, such as low vaginal pH, has to be proven.

Antibody-based immunotoxins against HCMV. HCMV can cause severe diseases in immunocompromised persons and establishes life-long infection in the human body [47]. Because the virus is highly species specific, it is not easily studied in animal models (except humanized mouse models). Instead, its murine counterpart MCMV is often used as a surrogate model for the study of virus replication and pathogenesis in vivo [48, 49]. Immunotoxins specific for cells infected with HCMV and MCMV have been constructed by linking polyclonal anti-HCMV and -MCMV IgG to gelonin, a type I ribosome-inactivating protein. Both immunotoxins failed to obtain sufficient anti-HCMV/anti-MCMV activities in vitro [50], indicating that other immunotoxins with improved antiviral activities are needed for in vivo studies. Examples of these are mAbs and pAbs conjugated to a deglycosylated ricin A chain for MCMV targeting. These

immunotoxins were more efficient than the gelonin-based anti-MCMV immunotoxin and were therefore evaluated *in vivo* in MCMV-infected SCID mice [51]. Unfortunately, they were both inadequate in their effects on survival [52] and their overall effect was weak in comparison to that of ganciclovir in mice. Further work is needed to determine whether more potent and efficient antibody-based immunotoxins against CMV can be found.

CHEMOKINE-BASED IMMUNOTOXINS FOR HCMV TARGETING VIA US28

The first chemokine-based immunotoxin targeting a viral GPCR has been reported recently [16]. The targeting molecule was not antibody-based, but instead was created by a series of modifications in the cognate chemokine-ligand for the HCMV-expressed chemokine receptor US28. GPCRs constitute the biggest protein family in the human genome and are targets for ~50% of all currently marketed drugs [53]. Based on their 7TM α -helices, they are also known as 7TM receptors. The chemokine receptors and ligands constitute important parts of a very complex system that controls leukocyte movements during homeostasis and inflammation. Herpesvirus genomes have evolved an extraordinary repertoire of tools designed to ensure successful infectivity and propagation. A large fraction of these tools involves virus-encoded 7TM receptors and ligands, most of which have high genetic and functional homology to either chemokines or chemokine receptors. Thus, HCMV devotes a significant part of its genome to immune modulatory gene homologs, as the virus-encoded GPCRs UL33, UL78, US27, and US28, with US28 being a functional chemokine receptor [54]. Several pharmacological and cellular properties of US28 suggest that this vGPCR would be suitable for targeting of HCMV in an immunotoxin-based strategy. First, although US28 binds a broad spectrum of chemokines as part of its proposed immune evasive function as a chemokine scavenger, it shows high selectivity and enhanced binding for the CX₃C chemokine CX₃CL1 [55]. Because CX₃CL1 binds only 1 human chemokine receptor, CX₃CR1, the potential of unwanted off-target effects of a CX₃CL1-based immunotoxin strategy is decreased. Second, CX₃CL1 consists of a chemokine domain, a mucin stalk, and a transmembrane domain. These structural characteristics suggest that this chemokine can sustain high-affinity binding to US28 when the C-terminally attached mucin-like stalk is replaced by another protein (e.g., the cytotoxic domains of PE). Third, detailed studies indicate that most of the US28 receptors localize away from the cell surface in endosomes [56, 57]. This distribution results from rapid, constitutive, and ligand-independent receptor internalization [58], a feature well-suited for efficient intracellular delivery of immunotoxins. Based on the molecular characteristics of US28 and its defined ligand profile, an immunotoxin was designed consisting of the chemokine domain CX₃CL1 and the translocation and cytotoxicity domains of PE (**Fig. 2**). It was given the name CX₃CL1-FTP to highlight that the target moiety was based on a chemokine, not an antibody [16]. CX₃CL1-FTP binds to US28 with higher affinity, kills US28-expressing cells with higher potency, and more efficiently controls virus replication and release of virus particles than does ganciclovir. Moreover,

CX₃CL1-FTP is capable of controlling virus replication of a ganciclovir-resistant HCMV strain—a highly important property for treatment of patients who have an increasing clinical challenge of infection with ganciclovir-resistant HCMV strains. As CX₃CL1-FTP also killed cells expressing the human chemokine receptor CX₃CR1 (albeit much less efficiently), a rational design strategy was applied to further enhance the selectivity of the immunotoxin molecule toward US28 [16]. A single-point mutation (Phe⁴⁹ to Ala) in CX₃CL1 retained high-affinity binding to US28 and reduced affinity to CX₃CR1, providing a favorable selectivity profile toward US28. The selectivity-optimized immunotoxin F49A-FTP exhibited far superior control of HCMV infection *in vivo* in the SCID-hu mice model compared with ganciclovir [16, 59]. The efficacy, combined with the rational design of a selective chemokine as the target molecule, demonstrates the high therapeutic potential of this drug candidate. Many questions clearly remain, including the capacity for development of F49A-FTP-resistance *in vivo* and toxicity and the immunogenicity associated with F49A-FTP.

7TM receptors as potential antiviral immunotoxin targets

As evident from the presentation of F49A-FTP, the immunotoxin drug candidate for the treatment of HCMV, rationally designed immunotoxins targeting virus-expressed receptors may provide promising drug targets, not only for anti-HCMV therapy, but also other virus-encoded 7TM receptors [60–63].

The EBV-encoded BILF1 receptor. EBV encodes 1 constitutively active tumorigenic receptor, EBV-BILF1 [61, 62, 64]. It has been suggested that this 7TM receptor is involved in the pathogenesis of EBV-associated malignancies, presumably in a signaling-dependent manner. The molecular properties of EBV-BILF1 indicate that this receptor is a promising drug target and is suitable for immunotoxin targeting. Cell surface expression of EBV-BILF1 can be detected during the lytic phase of infection, and even low receptor expression levels were detectable in latency [65]—an important feature for targeting EBV-associated cancers as only a few viral gene products are expressed. Moreover the receptor is constitutively internalized into the cell [66], which is important for efficient toxin delivery into cancer cells. However, as EBV-BILF1 is an orphan receptor, a ligand has to be identified for the immunotoxin design.

The KSHV-encoded chemokine receptor ORF74. This broad-spectrum chemokine receptor seems highly suitable for immunotoxin targeting. In itself, ORF74 can induce the onset of Kaposi's sarcoma-like lesions through the activation of a complex network of signaling pathways that involve the autocrine and paracrine activation of proliferative, proinflammatory, and angiogenic pathways. Targeting ORF74-mediated signaling by inhibiting individual pathways has been shown to have insufficient therapeutic potential to cure several cancers [67]. In contrast, using immunotoxins designed to target KSHV-infected cells through ORF74 seems a valid approach to efficiently kill KSHV-infected cells; hence, the abrogation of oncogenic signaling events. ORF74 has a defined chemokine ligand profile [68–70] and is internalized in response to human CXCL1 and -8 [71]. Thus, a rational chemokine-based immunotoxin strategy in homology to the strategy outlined above for US28 and CX₃CL1 could be applied.




Figure 2. Selective killing of HCMV infected cells by F49A-FTP. The FTP consisting of the CX₃CL1 variant F49A and the cytotoxic domains of PE binds selectively to US28 (1), and the internalization of the FTP is triggered by internalization of the bound CX₃CL1 variant to US28 (2). The release of the CX₃CL1 variant is achieved by proteolytic cleavage (3), and the protein synthesis is inhibited by PE, leading to the killing of the infected cell (4).

In addition to the viral 7TM receptors, several viruses exploit host-encoded receptors by different means: 1) by up-regulating them in the same manner that EBV up-regulates EB12 [72], 2) by using them as cell entry cofactors [73–76], or 3) by encoding ligands (agonists and antagonists) for endogenous receptors, as vMIP1–3 is encoded for KSHV [77–79]. In theory, immunotoxins could also target these 3 methods. For the up-regulated receptors, such as EB12 (also known as GPR183), it has been suggested that the up-regulation improves virus replication, and that it could be important for antiviral immune defense [80, 81]. The role of EB12 in the EBV life cycle is still uncertain [81]. If EBV benefits from high EB12 expression, an immunotoxin targeting EB12 could provide an efficient and specific way to inhibit EBV-associated diseases. A possible drawback of this approach would be cytotoxic side effects in all EB12-expressing cells (B cells, T cells, macrophages, dendritic cells, and many others) [82]—effects that could be reduced by lowering the dose. However the reduction, in turn, could lead to inefficient immunotoxin targeting [83, 84].

FUTURE DIRECTIONS AND LIMITATIONS OF ANTIVIRAL IMMUNOTOXINS

For future antiviral immunotoxins to be successful, they must be efficient, with low toxicity. This efficiency can be obtained by using the following criteria: 1) The target of the immunotoxins must be highly disease-specific to limit side effects. Immunotoxins targeting the viral genome or virus-encoded proteins expressed on the surface of virions and infected cells are efficient targets, as these molecules are not normally expressed on human cells. 2) The target must be expressed in both the latent and the lytic phase of the virus cycle, to completely eradicate the virus infection. Indeed, although effective killing of lytically infected cells is not enough to eradicate viruses that also have a latent stage, it is sufficient in most cases to treat acute infection. 3) The target expressed on the surface of infected cells

must have a rapid internalizing capability for the immunotoxin to be efficiently delivered to the intracellular environment. 4) The immunotoxin must bypass the host's immune system as generation of neutralizing antibodies to the immunotoxin prevents continued treatment and retreatment. It is especially the toxin moiety of the immunotoxin that can be immunogenic, as this is often derived from bacteria or plant (nonhuman) sources. To circumvent this problem, patients could be treated with immunosuppressive drugs to prevent or delay the production of neutralizing antibodies [85].

CONCLUSION

Current development of antiviral immunotoxins is an emerging field with constantly improved and innovative methods for successful application. Research has developed combination therapies with immunotoxins that are beneficial in viral treatment, which further highlights the promise of successful application of antiviral immunotoxins.

AUTHORSHIP

K.S., M.H.J., T.N.K. and M.M.R. contributed to the development of ideas, literature research, and writing and editing the text, table, and figures.

ACKNOWLEDGMENTS

The authors thank Line Barington for critical reading of the manuscript and helpful comments.

DISCLOSURE

The authors declare no conflicts of interest.

REFERENCES

- Potala, S., Sahoo, S. K., Verma, R. S. (2008) Targeted therapy of cancer using diphtheria toxin-derived immunotoxins. *Drug Discov. Today* **13**, 807–815.
- Choudhary, S., Mathew, M., Verma, R. S. (2011) Therapeutic potential of anticancer immunotoxins. *Drug Discov. Today* **16**, 495–503.
- Antignani, A., Fitzgerald, D. (2013) Immunotoxins: the role of the toxin. *Toxins (Basel)* **5**, 1486–1502.
- Mazor, R., Eberle, J. A., Hu, X., Vassall, A. N., Onda, M., Beers, R., Lee, E. C., Kreitman, R. J., Lee, B., Baker, D., King, C., Hassan, R., Benhar, I., Pastan, I. (2014) Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. *Proc. Natl. Acad. Sci. USA* **111**, 8571–8576.
- Madhumathi, J., Devilakshmi, S., Sridevi, S., Verma, R. S. (2015) Immunotoxin therapy for hematologic malignancies: where are we heading? *Drug Discov. Today* **00**, 1–8.
- Foss, F. M., Bacha, P., Osann, K. E., Demierre, M. F., Bell, T., Kuzel, T. (2001) Biological correlates of acute hypersensitivity events with DAB (389)IL-2 (denileukin difitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. *Clin. Lymphoma* **1**, 298–302.
- Foss, F., Demierre, M. F., DiVenuti, G. (2005) A phase-I trial of bexarotene and denileukin difitox in patients with relapsed or refractory cutaneous T-cell lymphoma. *Blood* **106**, 454–457.
- Frankel, A. E., Fleming, D. R., Hall, P. D., Powell, B. L., Black, J. H., Leftwich, C., Gartenhaus, R. (2003) A phase II study of DT fusion protein denileukin difitox in patients with fludarabine-refractory chronic lymphocytic leukemia. *Clin. Cancer Res.* **9**, 3555–3561.
- Smaglo, B. G., Aldeghaither, D., Weiner, L. M. (2014) The development of immunocjugates for targeted cancer therapy. *Nat. Rev. Clin. Oncol.* **11**, 637–648.
- Ansell, S. M., Horwitz, S. M., Engert, A., Khan, K. D., Lin, T., Strair, R., Keler, T., Graziano, R., Hlanset, D., Yellin, M., Fischkoff, S., Assad, A., Borchmann, P. (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. *J. Clin. Oncol.* **25**, 2764–2769.
- Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., Yang, Y., Sievers, E. L., Kennedy, D. A., Shustov, A. (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. *J. Clin. Oncol.* **30**, 2190–2196.
- Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P. S., White, C. A. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. *J. Clin. Oncol.* **20**, 3262–3269.
- Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., Wahl, R. L., Knox, S. J., Vose, J. M. (2001) Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. *J. Clin. Oncol.* **19**, 3918–3928.
- Song, H., Sgouros, G. (2011) Radioimmunotherapy of solid tumors: searching for the right target. *Curr. Drug Deliv.* **8**, 26–44.
- Hassan, R., Miller, A. C., Sharon, E., Thomas, A., Reynolds, J. C., Ling, A., Kreitman, R. J., Miettinen, M. M., Steinberg, S. M., Fowler, D. H., Pastan, I. (2013) Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. *Sci. Transl. Med.* **5**, 208ra147.
- Spies, K., Jeppesen, M. G., Malmgaard-Clausen, M., Krzykowski, K., Dulal, K., Cheng, T., Hjortø, G. M., Larsen, O., Burg, J. S., Jarvis, M. A., Christopher Garcia, K., Zhu, H., Kledal, T. N., Rosenkilde, M. M. (2015) Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo. *Proc. Natl. Acad. Sci. USA* **112**, 8427–8432.
- Zhu, J.-D., Meng, W., Wang, X.-J., Wang, H.-C. R. (2015) Broad-spectrum antiviral agents. *Front. Microbiol.* **6**, 517.
- Denton, P. W., Long, J. M., Wietgreffe, S. W., Sykes, C., Spagnuolo, R. A., Snyder, O. D., Perkey, K., Archin, N. M., Choudhary, S. K., Yang, K., Hudgens, M. G., Pastan, I., Haase, A. T., Kashuba, A. D., Berger, E. A., Margolis, D. M., Garcia, J. V. (2014) Targeted cytotoxic therapy kills persisting HIV infected cells during ART. *PLoS Pathog.* **10**, e1003872.
- Geoghegan, E. M., Zhang, H., Desai, P. J., Biragyn, A., Markham, R. B. (2015) Antiviral activity of a single-domain antibody immunotoxin binding to glycoprotein D of herpes simplex virus 2. *Antimicrob. Agents Chemother.* **59**, 527–535.
- Till, M. A., Zolla-Pazner, S., Gorny, M. K., Patton, J. S., Uhr, J. W., Vitetta, E. S. (1989) Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. *Proc. Natl. Acad. Sci. USA* **86**, 1987–1991.
- Pincus, S. H., Wehrly, K., Chesebro, B. (1989) Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. *J. Immunol.* **142**, 3070–3075.
- Till, M. A., Ghetie, V., Gregory, T., Patzer, E. J., Porter, J. P., Uhr, J. W., Capon, D. J., Vitetta, E. S. (1988) HIV-infected cells are killed by rCD4-ricin A chain. *Science* **242**, 1166–1168.
- Chaudhary, V. K., Mizukami, T., Fuerst, T. R., FitzGerald, D. J., Moss, B., Pastan, I., Berger, E. A. (1988) Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. *Nature* **335**, 369–372.
- Ananworanich, J. (2015) What will it take to cure HIV? *Top. Antivir. Med.* **23**, 80–84.
- Aullo, P., Alcamí, J., Popoff, M. R., Klatzmann, D. R., Murphy, J. R., Boquet, P. (1992) A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV. *EMBO J.* **11**, 575–583.
- Ramachandran, R. V., Katzenstein, D. A., Wood, R., Batts, D. H., Merigan, T. C. (1994) Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. *J. Infect. Dis.* **170**, 1009–1013.
- Dadachova, E., Kitchen, S. G., Bristol, G., Baldwin, G. C., Revskaya, E., Empig, C., Thornton, G. B., Gorny, M. K., Zolla-Pazner, S., Casadevall, A. (2012) Pre-clinical evaluation of a ²¹³Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. *PLoS One* **7**, e31866.
- Chun, T. W., Davey, R. T., Jr., Ostrowski, M., Shawn Justement, J., Engel, D., Mullins, J. I., Fauci, A. S. (2000) Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. *Nat. Med.* **6**, 757–761.
- Kennedy, P. E., Bera, T. K., Wang, Q.-C., Gallo, M., Wagner, W., Lewis, M. G., Berger, E. A., Pastan, I. (2006) Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. *J. Leukoc. Biol.* **80**, 1175–1182.
- Volberding, P. A., Deeks, S. G. (2010) Antiretroviral therapy and management of HIV infection. *Lancet* **376**, 49–62.
- Dieffenbach, C. W., Fauci, A. S. (2011) Thirty years of HIV and AIDS: future challenges and opportunities. *Ann. Intern. Med.* **154**, 766–771.
- Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., Hendrickson, W. A. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. *Nature* **393**, 648–659.
- Ashorn, P., Englund, G., Martin, M. A., Moss, B., Berger, E. A. (1991) Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages. *J. Infect. Dis.* **163**, 703–709.
- Berger, E. A., Pastan, I. (2010) Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. *PLoS Pathog.* **6**, e1000803.
- Goldstein, H., Pettoello-Mantovani, M., Bera, T. K., Pastan, I. H., Berger, E. A. (2000) Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice. *J. Infect. Dis.* **181**, 921–926.
- Melkus, M. W., Estes, J. D., Padgett-Thomas, A., Gatlin, J., Denton, P. W., Othieno, F. A., Wege, A. K., Haase, A. T., Garcia, J. V. (2006) Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. *Nat. Med.* **12**, 1316–1322.
- Dourmishv, L. A., Dourmishv, A. L., Palmeri, D., Schwartz, R. A., Lukac, D. M. (2003) Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. *Microbiol. Mol. Biol. Rev.* **67**, 175–212.
- Cesarman, E., Chang, Y., Moore, P. S., Said, J. W., Knowles, D. M. (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. *N. Engl. J. Med.* **332**, 1186–1191.
- Pellet, P. E., Roizman, B. (2007) The family of Herpesviridae: a brief introduction. In *Fields' Virology*, 5th ed. (Knipe, D. M., Howley, P. M., eds.), Lippincott Williams & Wilkins, Philadelphia, 2479–2500.
- Cai, Y., Berger, E. A. (2011) An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection. *Antiviral Res.* **90**, 143–150.
- Chatterjee, D., Chandran, B., Berger, E. A. (2012) Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein. *MAbs* **4**, 233–242.
- Wu, L., Renne, R., Ganem, D., Forghani, B. (2000) Human herpesvirus 8 glycoprotein K8.1: expression, post-translational modification and localization analyzed by monoclonal antibody. *J. Clin. Virol.* **17**, 127–136.
- Looker, K. J., Garnett, G. P., Schmid, G. P. (2008) An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. *Bull. World Health Organ.* **86**, 805–812 (A.).
- Johnston, C., Koelle, D. M., Wald, A. (2011) HSV-2: in pursuit of a vaccine. *J. Clin. Invest.* **121**, 4600–4609.
- Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E. B., Bendahman, N., Hamers, R. (1993) Naturally occurring antibodies devoid of light chains. *Nature* **363**, 446–448.

46. Geoghegan E., Zhang H., Desai P. J., Biragyn A., Markham R. B. (2015) Antiviral activity of single domain antibody immunotoxin binding to glycoprotein D of herpes simplex virus. *Antimicrob. Agents Chemother.* **59**, 527–535.
47. Steiningger, C. (2007) Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. *Clin. Microbiol. Infect.* **13**, 953–963.
48. Hudson, J. B. (1979) The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections. *Arch. Virol.* **62**, 1–29.
49. Fliss, P. M., Brune, W. (2012) Prevention of cellular suicide by cytomegaloviruses. *Viruses* **4**, 1928–1949.
50. Barnett, B. B., Smee, D. F., Malek, S. M., Sidwell, R. W. (1995) Selective cytotoxicity towards cytomegalovirus-infected cells by immunotoxins consisting of gelonin linked to anti-cytomegalovirus antibody. *Antiviral Res.* **28**, 93–100.
51. Barnett, B. B., Smee, D. F., Malek, S. M., Sidwell, R. W. (1996) Selective cytotoxicity of ricin A chain immunotoxins towards murine cytomegalovirus-infected cells. *Antimicrob. Agents Chemother.* **40**, 470–472.
52. Smee, D. F., Sidwell, R. W., Barnett, B. B. (1996) Combination of antiviral immunotoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infections. *Antiviral Res.* **32**, 165–171.
53. Overington, J. P., Al-Lazikani, B., Hopkins, A. L. (2006) How many drug targets are there? *Nat. Rev. Drug Discov.* **5**, 993–996.
54. Chee, M. S., Satchwell, S. C., Preddie, E., Weston, K. M., Barrell, B. G. (1990) Human cytomegalovirus encodes three G protein-coupled receptor homologues. *Nature* **344**, 774–777.
55. Kledal, T. N., Rosenkilde, M. M., Schwartz, T. W. (1998) Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28. *FEBS Lett.* **441**, 209–214.
56. Fraile-Ramos, A., Kledal, T. N., Pelchen-Matthews, A., Bowers, K., Schwartz, T. W., Marsh, M. (2001) The human cytomegalovirus US28 protein is located in endocytic vesicles and undergoes constitutive endocytosis and recycling. *Mol. Biol. Cell* **12**, 1737–1749.
57. Droese, J., Mokros, T., Hermosilla, R., Schüle, R., Lipp, M., Höpken, U. E., Rehm, A. (2004) HCMV-encoded chemokine receptor US28 employs multiple routes for internalization. *Biochem. Biophys. Res. Commun.* **322**, 42–49.
58. Fraile-Ramos, A., Kohout, T. A., Waldhoer, M., Marsh, M. (2003) Endocytosis of the viral chemokine receptor US28 does not require beta-arrestins but is dependent on the clathrin-mediated pathway. *Traffic* **4**, 243–253.
59. Brown, J. M., Kaneshima, H., Mocarski, E. S. (1995) Dramatic interstrain differences in the replication of human cytomegalovirus in SCID-hu mice. *J. Infect. Dis.* **171**, 1599–1603.
60. Bais, C., Santomasso, B., Coso, O., Arvanitakis, L., Raaka, E. G., Gutkind, J. S., Asch, A. S., Cesarman, E., Gershengorn, M. C., Mesri, E. A. (1998) G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. *Nature* **391**, 86–89.
61. Paulsen, S. J., Rosenkilde, M. M., Eugen-Olsen, J., Kledal, T. N. (2005) Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. *J. Virol.* **79**, 536–546.
62. Beisser, P. S., Verzijl, D., Gruijthuisen, Y. K., Beuken, E., Smit, M. J., Leurs, R., Bruggeman, C. A., Vink, C. (2005) The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase. *J. Virol.* **79**, 441–449.
63. Rosenkilde, M. M. (2005) Virus-encoded chemokine receptors: putative novel antiviral drug targets. *Neuropharmacology* **48**, 1–13.
64. Lyngaa, R., Nørregaard, K., Kristensen, M., Kubale, V., Rosenkilde, M. M., Kledal, T. N. (2010) Cell transformation mediated by the Epstein-Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling. *Oncogene* **29**, 4388–4398.
65. Tierney, R. J., Shannon-Lowe, C. D., Fitzsimmons, L., Bell, A. I., Rowe, M. (2015) Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA. *Virology* **474**, 117–130.
66. Spiess, K., Fares, S., Sparre-Ulrich, A. H., Hilgenberg, E., Jarvis, M. A., Ehlers, B., Rosenkilde, M. M. (2015) Identification and functional comparison of seven-transmembrane G-protein-coupled BILF1 receptors in recently discovered nonhuman primate lymphocryptoviruses. *J. Virol.* **89**, 2253–2267.
67. Vischer, H. F., Siderius, M., Leurs, R., Smit, M. J. (2014) Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases? *Nat. Rev. Drug Discov.* **13**, 123–139.
68. Rosenkilde, M. M., Kledal, T. N., Bräuner-Osborne, H., Schwartz, T. W. (1999) Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF74. *J. Biol. Chem.* **274**, 956–961.
69. Arvanitakis, L., Geras-Raaka, E., Varma, A., Gershengorn, M. C., Cesarman, E. (1997) Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. *Nature* **385**, 347–350.
70. Gershengorn, M. C., Geras-Raaka, E., Varma, A., Clark-Lewis, I. (1998) Chemokines activate Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture. *J. Clin. Invest.* **102**, 1469–1472.
71. De Munnik, S. M., Kooistra, A. J., van Offenbeek, J., Nijmeijer, S., de Graaf, C., Smit, M. J., Leurs, R., Vischer, H. F. (2015) The Viral G protein-coupled receptor ORF74 hijacks β -arrestins for endocytic trafficking in response to human chemokines. *PLoS One* **10**, e0124486.
72. Birkenbach, M., Josefson, K., Yalamanchili, R., Lenoir, G., Kieff, E. (1993) Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors. *J. Virol.* **67**, 2209–2220.
73. Doms, R. W. (2000) Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. *Virology* **276**, 229–237.
74. Weiss, R. A. (2013) Thirty years on: HIV receptor gymnastics and the prevention of infection. *BMC Biol.* **11**, 57.
75. Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S., Landau, N. R. (1997) Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. *J. Exp. Med.* **185**, 621–628.
76. Scarlati, G., Tresoldi, E., Björndal, A., Fredriksson, R., Colognesi, C., Deng, H. K., Malnati, M. S., Plebani, A., Siccardi, A. G., Littman, D. R., Fenyo, E. M., Lusso, P. (1997) In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. *Nat. Med.* **3**, 1259–1265.
77. Kledal, T. N., Rosenkilde, M. M., Coulin, F., Simmons, G., Johnsen, A. H., Alouani, S., Power, C. A., Lüttichau, H. R., Gerstoft, J., Clapham, P. R., Clark-Lewis, I., Wells, T. N., Schwartz, T. W. (1997) A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. *Science* **277**, 1656–1659.
78. Moore, P. S., Boshoff, C., Weiss, R. A., Chang, Y. (1996) Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. *Science* **274**, 1739–1744.
79. Stüne, J. T., Wood, C., Hill, M., Epp, A., Raport, C. J., Schweickart, V. L., Endo, Y., Sasaki, T., Simmons, G., Boshoff, C., Clapham, P., Chang, Y., Moore, P., Gray, P. W., Chantry, D. (2000) KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. *Blood* **95**, 1151–1157.
80. Gatto, D., Brink, R. (2013) B cell localization: regulation by EB12 and its oxysterol ligand. *Trends Immunol.* **34**, 336–341.
81. Arfelt, K. N., Fares, S., Rosenkilde, M. M. (2015) EBV, the human host, and the 7TM receptors: defense or offense? *Prog. Mol. Biol. Transl. Sci.* **129**, 395–427.
82. Rosenkilde, M. M., Bened-Jensen, T., Andersen, H., Holst, P. J., Kledal, T. N., Lüttichau, H. R., Larsen, J. K., Christensen, J. P., Schwartz, T. W. (2006) Molecular pharmacological phenotyping of EB12: an orphan seven-transmembrane receptor with constitutive activity. *J. Biol. Chem.* **281**, 13199–13208.
83. Madhumathi, J., Devilashmi, S., Sridevi, S., Verma, R. S. (2015) Immunotoxin therapy for hematologic malignancies: where are we heading? *Drug Discov. Today* doi:10.1016/j.drudis.2015.05.002 [Epub ahead of print].
84. Litvak-Greenfield, D., Benhar, I. (2012) Risks and untoward toxicities of antibody based immunoconjugates. *Adv. Drug Deliv. Rev.* **64**, 1782–1799.
85. Weldon, J. E., Pastan, I. (2011) A guide to taming a toxin: recombinant immunotoxins constructed from *Pseudomonas* exotoxin A for the treatment of cancer. *FEBS J.* **278**, 4683–4700.
86. Bjorn, M. J., Ring, D., Frankel, A. (1985) Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. *Cancer Res.* **45**, 1214–1221.
87. Weiner, L. M., O'Dwyer, J., Kitson, J., Comis, R. L., Frankel, A. E., Bauer, R. J., Konrad, M. S., Groves, E. S. (1989) Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. *Cancer Res.* **49**, 4062–4067.
88. Zovickian, J., Johnson, V. G., Youle, R. J. (1987) Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. *J. Neurosurg.* **66**, 850–861.
89. Laske, D. W., Muraszko, K. M., Oldfield, E. H., DeVroom, H. L., Sung, C., Dedrick, R. L., Simon, T. R., Colandrea, J., Copeland, C., Katz, D., Greenfield, L., Groves, E. S., Houston, L. L., Youle, R. J. (1997) Intraventricular Immunotoxin Therapy for Leptomeningeal Neoplasia. *Neurosurg.* **4**, 1039–1051.
90. Thompson, J., Stavrou, S., Weetall, M., Hexham, J. M., Digan, M. E., Wang, Z., Woo, J. H., Yu, Y., Mathias, A., Liu, Y. Y., Ma, S., Gordienko, I., Lake, P., Neville, D. M. (2001) Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for *in vivo* T-cell depletion. *Protein Eng.* **14**, 1035–1041.
91. Frankel, A. E., Zuckero, S. L., Mankin, A. A., Grable, M., Mitchell, K., Lee, Y. J., Neville, D. M., Woo, J. H. (2009) Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. *Curr. Drug Targets* **10**, 104–109.
92. Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, L. M., Chari, R. V. J., Lutz, R. J., Wong, W. L. T., Jacobson, F. S., Koeppe, H., Schwall, R. H., Kenkare-Mitra, S. R., Spencer, S. D., Sliwkowski, M. X. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. *Cancer Res.* **68**, 9280–9290.

93. Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J., Sliwkowski, M. X., Jacobson, F., Lutzker, S. G., Burris, H. A. (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive MBC. *J. Clin. Oncol.* **28**, 2698–2704.
94. Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., Amler, L., Zheng, M., Chu, Y., Klencke, B., O'Shaughnessy, J. A. (2011) Phase II study of the anti-body drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. *J. Clin. Oncol.* **29**, 398–405.
95. Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D., Diéras, V., Guardino, E., Fang, L., Lu, M. W., Olsen, S., Blackwell, K. (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. *N. Engl. J. Med.* **367**, 1783–1791.
96. Krop, I. E., LoRusso, P., Miller, K. D., Modi, S., Yardley, D., Rodriguez, G., Guradino, E., Lu, M., Zheng, M., Girish, S., Amler, L., Winer, E. P., Rugo, H. S. (2012) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive MBC who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane and capecitabine. *J. Clin. Oncol.* **30**, 3234–3241.
97. Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., Chu, Y., Perez, E. A. (2013) Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive MBC (2013). *J. Clin. Oncol.* **31**, 1157–1163.
98. Miller, K. D., Dieras, V., Harbeck, N., Andre, F., Mahtani, R. L., Gianni, L., Albain, K. S., Crivellari, D., Fang, L., Michelson, G., de Haas, S. L., Burris, H. A. (2014) Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. *J. Clin. Oncol.* **32**, 1437–1444.
99. Krop, I. E., Kim, S., González-Martín, A., LoRusso, P. M., Ferrero, J., Smitt, M., Yu, R., Leung, A. C. F., Wildiers, H. (2014) Trastuzumab emtansine versus treatment of physician's choice for pre-treated HER2-positive advanced breast cancer (TH3RESA): a randomized, open-label, phase 3 trial. *Lancet Oncol.* **15**, 689–699.
100. Welslau, M., Diéras, V., Sohn, J., Hurvitz, S. A., Lalla, D., Fang, L., Althaus, B., Guardino, E., Miles, D. (2014) Patient reported outcomes from EMLIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. *Cancer* **120**, 642–651.
101. Lambert, J. M., Goldmacher, V. S., Collinson, A. R., Nadler, L. M., Blattler, W. A. (1991) An immunotoxin prepared with blocked ricin: A natural plant toxin adapted for therapeutic use. *Cancer Res.* **51**, 6236–6242.
102. Grossbard, M. L., Freedman, A. S., Ritz, J., Coral, F., Goldmacher, V. S., Eliseo, L., Spector, N. D. K., Lambert, J. M., Blattler, W. A., Taylor, J. A., Nadler, L. M. (1992) Serotherapy of B-cell neoplasms with anti-B4-blocked ricin-A: phase-I trial of daily bolus infusion. *Blood* **79**, 576–585.
103. Grossbard, M. L., Gribben, J. G., Freedman, A. S., Lambert, J. M., Kinsella, J., Rabinowe, S. N., Eliseo, L., Taylor, J. A., Blattler, W. A., Epstein, C. L., Nadler, L. M. (1993) Adjuvant immunotoxin therapy with anti-B4 blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. *Blood* **81**, 2263–2271.
104. Grossbard, M. L., Fidiás, P., Kinsella, J., O'Toole, J., Lambert, J. M., Blattler, W. A., Esseltine, D., Braman, G., Nadler, L. M., Anderson, K. C. (1998) Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. *Br. J. Haematol.* **102**, 509–515.
105. Multani, P. S., O'Day, S., Nadler, L. M., Grossbard, M. L. (1998) Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunocombination in patients with relapsed B-cell non-Hodgkin's lymphoma. *Clin. Cancer Res.* **4**, 2599–2604.
106. Furman, R. R., Grossbard, M. L., Johnson, J. L., Pecora, A. L., Cassileth, P. A., Jung, S., Peterson, B. A., Nadler, L. M., Freedman, A., Bayer, R., Bartlett, N. L., Hurd, D. D., Cheson, B. D. (2011) A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. *Leuk. Lymphoma* **52**, 587–596.
107. Roy, D. C., Griffin, J. D., Belvin, M., Blattler, W. A., Lambert, J. M., Ritz, J. (1991) Anti-MY9-blocked ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells. *Blood* **77**, 2404–2412.
108. Myers, D. E., Irvin, J. D., Smith, R. S., Kuebelbeck, V. A., Uckun, F. M. (1991) Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials. *J. Immunol. Methods* **136**, 221–238.
109. Seibel, N. L., Krailo, M., O'Neill, K., Franklin, J., Uckun, F., Reaman, G. H. (1999) Phase I study of b43-PAP immunotoxin in combination with standard 4-drug induction for patients with CD19+ acute lymphoblastic leukemia (all) in relapse, a children's cancer group study. *Pediatr. Res.* **45**, 775–775.
110. Falini, B., Bolognesi, A., Flenghi, L., Tazzari, P. L., Broe, M. K., Stein, H., Durkop, H., Aversa, F., Corneli, P., Pizzolo, G., Barbabietola, G., Sabatini, E., Pileri, S., Martelli, M. F., Stirpe, F. (1992) Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. *Lancet* **339**, 1195–1196.
111. Tazzari, P. L., Bolognesi, A., De Toter, D., Falini, B., Lemoli, R. M., Soria, M. R., Pileri, S., Gobbi, M., Stein, H., Flenghi, L., Martelli, M. F., Stirpe, F. (1992) Ber-H2 (anti-CD30)-saporin immunotoxin: A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma. In vitro evaluation. *Br. J. Haematol.* **81**, 203–211.
112. Falini, B., Pasqualucci, L., Flenghi, L., et al. (1995) Anti-CD30 immunotoxins: Experimental and clinical studies. *Abstracts of the Fourth International Symposium on Immunotoxins* **160**.
113. Mansfield, E., Amlot, P., Pastan, I., FitzGerald, D. J. (1997) Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. *Blood* **90**, 2020–2026.
114. Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D. J., Pastan, I. (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. *N. Engl. J. Med.* **345**, 241–247.
115. Kreitman, R. J., Squires, D. R., Stetler-Stevenson, M., Noel, P., FitzGerald, D. J., Wilson, W. H., Pastan, I. (2005) Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. *J. Clin. Oncol.* **23**, 6719–6729.
116. Kreitman, R. J., Stetler-Stevenson, M., Margulies, I., Noel, P., FitzGerald, D. J., Wilson, W. H., Pastan, I. (2009) Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. *J. Clin. Oncol.* **27**, 2983–2990.
117. Wayne, A. S., Kreitman, R. J., Findley, H. W., Lew, G., Delbrook, C., Steinberg, S. M., Stetler-Stevenson, M., FitzGerald, D. J., Pastan, I. (2010) Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. *Clin. Cancer Res.* **16**, 1894–1903.
118. Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejnial, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., Law, C., Doronina, S. O., Siegall, C. B., Senter, P. D., Wahl, A. F. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. *Blood* **102**, 1458–1465.
119. Doronina, S. O., Toki, B. E., Torgov, M. Y., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. *Nat. Biotechnol.* **21**, 778–784.
120. Bartlett, N. L., Younes, A., Carabasi, M. H., Forero, A., Rosenblatt, J. D., Leonard, J. P., Bernstein, S. H., Bociek, R. G., Lorenz, J. M., Hart, B. W., Barton, J. (2008) A phase I multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30⁺ hematologic malignancies. *Blood* **111**, 1848–1854.
121. Forero-Torres, A., Leonard, J. P., Younes, A., Rosenblatt, J. D., Brice, P., Bartlett, N. L., Bosly, A., Pinter-Brown, L., Kennedy, D., Sievers, E. L., Gopal, A. K. (2009) A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. *Br. J. Haematol.* **146**, 171–179.
122. Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., Forero-Torres, A. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. *N. Engl. J. Med.* **363**, 1812–1821.
123. Fanale, M. A., Forero-Torres, A., Rosenblatt, J. D., Advani, R. H., Franklin, A. R., Kennedy, D. A., Han, T. H., Sievers, E. L., Bartlett, N. L. (2011) A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. *Clin. Cancer Res.* **18**, 248–255.
124. Debinski, W., Obiri, N. I., Pastan, I., Puri, R. K. (1995) A novel chimeric protein composed of human interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. *J. Biol. Chem.* **270**, 16775–16780.
125. Kunwar, S., Prados, M. D., Chang, S. M., Berger, M. S., Lang, F. F., Piepmeier, J. M., Sampson, J. H., Ram, Z., Gutin, P. H., Gibbons, R. D., Aldape, K. D., Croteau, D. J., Sherman, J. W., Puri, R. K. (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intracranial Study Group. *J. Clin. Oncol.* **25**, 837–844.
126. Vogelbaum, M. A., Sampson, J. H., Kunwar, S., Chang, S. M., Shaffrey, M., Asher, A. L., Lang, F. F., Croteau, D., Parker, K., Grahn, A. Y., Sherman, J. W., Husain, S. R., Puri, R. K. (2007) Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase I study of final safety results. *Neurosurgery* **61**, 1031–1037.
127. Kunwar, S., Chang, S., Westphal, M., Vogelbaum, M., Sampson, J., Barnett, G., Shaffrey, M., Ram, Z., Piepmeier, J., Prados, M., Croteau, D., Pedain, C., Leland, P., Husain, S. R., Joshi, B. H., Puri, R. K. (2010) Phase III randomized trial of CED of IL13-PE38QQQR vs Gliadel wafers for recurrent glioblastoma. *Neuro-oncol.* **12**, 871–881.
128. Jansen, B., Vallera, D. A., Jaszcz, W. B., Nguyen, D., Kersey, J. H. (1992) Successful treatment of human acute T-cell leukemia in scid mice using the anti-CD7-deglycosylated ricin a-chain immunotoxin da7. *Cancer Res.* **52**, 1314–1321.

129. Frankel, A. E., Laver, J. H., Willingham, M. C., Burns, L. J., Kersey, J. H., Valleria, D. A. (1997) Therapy of patients with t-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-rich a chain immunotoxin. *Leuk. Lymphoma* **26**, 287–298.
130. Williams, D., Parker, K., Bacha, P., Bishai, W., Borowski, M., Genbauffe, F., Strom, T., Murphy, J. (1987) Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. *Protein Eng.* **1**, 493–498.
131. LeMaistre, C. F., Meneghetti, C., Rosenblum, M., Reuben, J., Parker, K., Shaw, J., Woodworth, T., Parkinson, D. R. (1992) Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. *Blood* **79**, 2547–2554.
132. LeMaistre, C. F., Craig, F. E., Meneghetti, C., McMullin, B., Parker, K., Reuben, J., Boldt, D. H., Rosenblum, M., Woodworth, T. (1993) Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. *Cancer Res.* **53**, 3930–3934.
133. Kuzel, T. M., Rosen, S. T., Gordon, L. I., Winter, J., Samuelson, E., Kaul, K., Roenigk, H. H., Nysten, P., Woodworth, T. (1993) Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. *Leuk. Lymphoma* **11**, 369–377.
134. Tepler, I., Schwartz, G., Parker, K., Charette, J., Kadin, M. E., Woodworth, T. G., Schnipper, L. E. (1994) Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. *Cancer* **73**, 1276–1285.
135. Williams, D. P., Snider, C. E., Strom, T. B., Murphy, J. R. (1990) Structure/Function Analysis of Interleukin-2-Toxin (DAB₄₈₆IL-2). *J. Biol. Chem.* **265**, 11885–11889.
136. LeMaistre, C. F., Saleh, M. N., Kuzel, T. M., Foss, F., Platanias, L. C., Schwartz, G., Ratain, M., Rook, A., Freytes, C. O., Craig, F., Reuben, J., Nichols, J. C. (1998) Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. *Blood* **91**, 399–405.
137. Saleh, M. N., LeMaistre, C. F., Kuzel, T. M., Foss, F., Platanias, L. C., Schwartz, G., Ratain, M., Rook, A., Freytes, C. O., Craig, F., Reuben, J., Sams, M. W., Nicholds, J. C. (1998) Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. *J. Am. Acad. Dermatol.* **39**, 63–73.
138. Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., Oseroff, A., Pinter-Brown, L., Bowen, G., Kuzel, T., Fivenson, D., Foss, F., Glode, M., Molina, A., Knobler, E., Stewart, S., Cooper, K., Stevens, S., Craig, F., Reuben, J., Bacha, P., Nichols, J. (2001) Pivotal phase III trial of two dose levels of denileukin difitox for the treatment of cutaneous T-cell lymphoma. *J. Clin. Oncol.* **19**, 376–388.
139. Frankel, A. E., Fleming, D. R., Hall, P. D., Powell, B. L., Black, J. H., Leftwich, C., Gartenhaus, R. (2003) A phase II study of DT fusion protein denileukin difitox in patients with fludarabine- refractory chronic lymphocytic leukemia. *Clin. Cancer Res.* **9**, 3555–3561.
140. Negro-Vilar, A., Prince, H. M., Duvic, M., Richardson, S., Sun, Y., Acosta, M. (2008) Efficacy and safety of denileukin difitox (DD) in cutaneous T-cell lymphoma (CTCL) patients: Integrated analysis of three large phase III trials. [Abstract] *J. Clin. Oncol.* **26**, 8551.
141. Prince, H. M., Duvic, M., Martin, A., Sterry, W., Assaf, C., Sun, Y., Straus, D., Acosta, M., Negro-Vilar, A. (2010) Phase III placebo-controlled trial of denileukin difitox for patients with cutaneous T-cell lymphoma. *J. Clin. Oncol.* **28**, 1870–1877.
142. Chan, C. H., Blazar, B. R., Eide, C. R., Kreitman, R. J., Valleria, D. A. (1995) A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells. *Blood* **86**, 2732–2740.
143. Perentesis, J. P., Waddick, K. G., Bendel, A. E., Shao, Y., Warman, B. E., Chandan-Langlie, M., Uckun, F. (1997) Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion protein directed against the human granulocyte macrophage colony-stimulating factor receptor. *Clin. Cancer Res.* **3**, 347–355.
144. Frankel, A. E., Powell, B. L., Hall, P. D., Case, L. D., Kreitman, R. J. (2002) Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. *Clin. Cancer Res.* **8**, 1004–1013.
145. Frankel, A. E., McCubrey, J. A., Miller, M. S., Delatte, S., Ramage, J., Kiser, M., Kucera, G. L., Alexander, R. L., Beran, M., Tagge, E. P., Kreitman, R. J., Hogge, D. E. (2000) Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. *Leukemia* **14**, 576–585.
146. Urieto, J. O., Liu, T., Black, J. H., Cohen, K. A., Hall, P. D., Willingham, M. C., Pennell, L. K., Hogge, D. E., Kreitman, R. J., Frankel, A. E. (2004) Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. *Protein Expr. Purif.* **33**, 123–133.
147. Batra, J. K., Kasprzyk, P. G., Bird, R. E., Pastan, I., King, C. R. (1992) Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. *Proc. Natl. Acad. Sci. USA* **89**, 5867–5871.
148. Reiter, Y., Brinkmann, U., Kreitman, R., Jung, S.-H., Lee, B., Pastan, I. (1994) Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. *Biochemistry* **33**, 5451–5459.
149. Pai-Scherf, L. H., Villa, J., Pearson, D., Watson, T., Liu, E., Willingham, M. C., Pastan, I. (1999) Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. *Clin. Cancer Res.* **5**, 2311–2315.
150. Hamann, P. R., Hollander, I., Kunz, A., Kunstman, M. Unpublished results.
151. Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., Bernstein, I. D. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. *Blood* **93**, 3678–3684.
152. Dowell, J. A., Korth-Bradley, J., Liu, H., King, P., Berger, M. S. (2001) Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. *J. Clin. Pharmacol.* **41**, 1206–1214.
153. Lo-Coco, F., Cimino, G., Breccia, M., Noguera, N. I., Diverio, D., Finolezzi, E., Pogliani, E. M., Bona, E. D., Micalizzi, C., Kropp, M., Venditti, A., Tafuri, A., Mandelli, F. (2004) Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. *Blood* **104**, 1995–1999.
154. Amadori, S., Suci, S., Stasi, R., Willemze, R., Mandelli, F., Selleslage, D., Denzlinger, C., Muus, P., Stauder, R., Berneman, Z., Pruijt, J., Nobile, F., Cassibba, V., Marie, J.-P., Beeldens, F., Baila, L., Vignetti, M., de Witte, T. (2005) Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase II study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. *Leukemia* **19**, 1768–1773.
155. Kernan, N. A., Knowles, R. W., Burns, M. J., Broxmeyer, H. E., Lu, L., Lee, H. M., Kawahata, R. T., Scannon, P. J., Dupont, B. (1984) Specific Inhibition of *In Vitro* Lymphocyte Transformation by an Anti-pan T Cell (gp67) Ricin A Chain Immunotoxin. *J. Immunol.* **133**, 137–146.
156. LeMaistre, C., Rosen, S., Frankel, A., Kornfeld, S., Sari, E., Meneghetti, C., Drajek, J., Fishwild, D., Scannon, P., Byers, V. (1991) Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. *Blood* **76**, 1173–1182.
157. Ghetie, V., Ghetie, M. A., Uhr, J. W., Vitetta, E. S. (1988) Large scale preparation of immunotoxins constructed with the Fab' fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain. *J. Immunol. Methods* **112**, 267–277.
158. Stone, M. J., Sausville, E. A., Fay, J. W., Headlee, D., Collins, R. H., Figg, W. D., Stedler-Stevenson, M., Jain, V., Jaffe, E. S., Solomon, D., Lush, R. M., Senderowicz, A., Ghetie, V., Schindler, J., Uhr, J. W., Vitetta, E. S. (1996) A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. *Blood* **88**, 1188–1197.
159. McGraw, K. J., Rosenblum, M. G., Cheung, L., Scheinberg, D. A. (1994) Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. *Cancer Immunol. Immunother.* **39**, 367–374.
160. Dean, A., Talpaz, M., Kantarjian, H., Faderl, S., Jabbour, E., Kashani, F. R., O'Brien, S. M., Rosenblum, M., Cortes, J. E. (2010) Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rGel in patients with advanced myeloid malignancies. *J. Clin. Oncol.* **28**, 217–221.
161. Borthakur, G., Rosenblum, M. G., Talpaz, M., Daver, N., Ravandi, F., Faderl, S., Freireich, E. J., Kadia, T., Garcia-Manero, G., Kantarjian, H., Cortes, J. E. (2013) Phase I study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. *Haematologica* **98**, 217–221.
162. Kreitman, R. J., Puri, R. K., Pastan, I. (1995) Increased antitumor activity of a circularly permuted IL4-toxin in mice with IL-4 receptor bearing human carcinoma. *Cancer Res.* **55**, 3357–3363.
163. Rand, R. W., Kreitman, R. J., Patronas, N., Varricchio, F., Pastan, I., Puri, R. K. (2000) Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. *Clin. Cancer Res.* **6**, 2157–2165.
164. Kawakami, M., Kawakami, K., Puri, R. K. (2003) Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. *J. Neurooncol.* **65**, 15–25.
165. Weber, F., Asher, A., Buchholz, R., Berger, M., Prados, M., Chang, S., Bruce, J., Hall, W., Rainov, N. G., Westphal, M., Warnick, R. E., Rand, R. W., Floeth, F., Rommel, F., Pan, H., Hingorani, V. N., Puri, R. K. (2003) Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. *J. Neurooncol.* **64**, 125–137.

166. Schnell, R., Linnartz, C., Katouzi, A. A., Schon, G., Bohlen, H., Horn-Lohrens, O., Parwaresch, R. M., Lange, H., Diehl, V., Lemke, H., Engert, A. (1995) Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells *in vitro* and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. *Int. J. Cancer* **63**, 238–244.
167. Schnell, R., Staak, O., Borchmann, P., Schwartz, C., Matthey, B., Hansen, H., Schindler, J., Ghetie, V., Vitetta, E. S., Diehl, V., Engert, A. (2002) A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30⁺ Hodgkin's and Non-Hodgkin's Lymphoma. *Clin. Cancer Res.* **8**, 1779–1786.
168. Pai, L. H., Batra, J. K., FitzGerald, D. J., Willingham, M. C., Pastan, I. (1991) Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of *Pseudomonas* exotoxin. *Proc. Natl. Acad. Sci. USA* **88**, 3358–3362.
169. Pai, L. H., Wittes, R., Setser, A., Willingham, M. C., Pastan, I. (1996) Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to *Pseudomonas* exotoxin. *Nat. Med.* **2**, 350–353.
170. Hassan, R., Williams-Gould, J., Watson, T., Pai-Scherf, L., Pastan, I. (2004) Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1. *Clin. Cancer Res.* **10**, 16–18.
171. Chaudhary, V. K., Queen, C., Junghans, R. P., Waldmann, T. A., FitzGerald, D. J., Pastan, I. (1989) A recombinant immunotoxin consisting of two antibody variable domains fused to *Pseudomonas* exotoxin. *Nature* **339**, 394–397.
172. Kreitman, R. J., Batra, J. K., Seetharam, S., Chaudhary, V. K., FitzGerald, D. J., Pastan, I. (1993) Single-chain immunotoxin fusions between anti-Tac and *Pseudomonas* exotoxin: Relative importance of the two toxin disulfide bonds. *Bioconjug. Chem.* **4**, 112–120.
173. Kreitman, R. J., Wilson, W. H., White, J. D., Statler-Stevenson, M., Jaffe, E. S., Giardina, S., Waldmann, T. A., Pastan, I. (2000) Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies. *J. Clin. Oncol.* **18**, 1622–1636.
174. Brinkmann, U., Pai, L. H., FitzGerald, D. J., Willingham, M., Pastan, I. (1991) B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. *Proc. Natl. Acad. Sci. USA* **88**, 8616–8620.
175. Brinkmann, U., Reiter, Y., Jung, S. H., Lee, B. K., Pastan, I. (1993) A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. *Proc. Natl. Acad. Sci. USA* **90**, 7538–7542.
176. Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J., Pastan, I. (2002) Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. *Clin. Cancer Res.* **8**, 995.
177. Kreitman, R. J., Tallman, M. S., Robak, T., Coutre, S., Wilson, W. H., Stetler-Stevenson, M. (1992) FritZGerald, D.J., Pastan, I. (2012) Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT -8015 and HA22) in Patients With Hairy Cell Leukemia. *J. Clin. Oncol.* **30**, 1822–1828.
178. Lorimer, I. A., Keppler-Hafkemeyer, A., Beers, R. A., Pegram, C. N., Bigner, D. D. (1996) Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. *Proc. Natl. Acad. Sci. USA* **93**, 14815–14820.
179. Goldmacher, V. S., Lambert, J. M., Blattler, W. A. (1992) The specific cytotoxicity of immunoconjugates containing blocked ricin is dependent on the residual binding capacity of blocked ricin: evidence that the membrane binding and A-chain translocation activities of ricin cannot be separated. *Biochem. Biophys. Res. Commun.* **183**, 758–766.
180. Lynch, T. J., Jr., Lambert, M. J., Coral, F., Shefner, J., Wen, P., Blattler, W. A., Collinson, A. R., Ariniello, P. D., Braman, G., Cook, S., Esseltine, D., Elias, A., Skarinand, A., Ritz, J. (1997) Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. *J. Clin. Oncol.* **15**, 723–734.
181. Fidiyas, P., Grossbard, M., Lynch, T. J., Jr. (2002) A Phase II Study of the Immunotoxin N901-Blocked Ricin in Small-Cell Lung Cancer. *Clin. Lung Cancer* **3**, 219–222.
182. Willingham, M. C., FitzGerald, D. J., Pastan, I. (1987) *Pseudomonas* exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model. *Proc. Natl. Acad. Sci. USA* **84**, 2474–2478.
183. Pai, L. H., Bookman, M. A., Ozols, R. F., Young, R. C., Smith, J. W., Longo, D. L., Gould, B., Frankel, A., McClay, E. F., Howell, S. (1991) Clinical evaluation of intraperitoneal *Pseudomonas* exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. *J. Clin. Oncol.* **9**, 2095–2103.
184. Shen, G. L., Li, J. L., Ghetie, M. A., May, R. D., Till, M., Brown, A. N., Relf, M., Knowles, P., Uhr, J. W., Janossy, G., Amlot, P., Vitetta, E. S., Thorpe, P. E. (1988) The evaluation of four anti-CD22 antibodies as ricin A chain-containing immunotoxins. *Int. J. Cancer* **42**, 792.
185. Amlot, P., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., Ghetie, V., Ramilo, O., Thorpe, P. E., Uhr, J. W., Vitetta, E. S. (1993) A phase I study of anti-CD22 deglycosylated ricin A chain immunotoxin in the treatment of B cell lymphomas resistant to conventional therapy. *Blood* **82**, 2624–2633.
186. Sausville, E. A., Headlee, D., Stetler-Stevenson, M., Jaffe, E. S., Solomon, D., Figg, W. D., Herdt, J., Kopp, W. C., Rager, H., Steinberg, S. M., Ghetie, V., Schindler, J., Uhr, J., Wittes, R. E., Vitetta, E. S. (1995) Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. *Blood* **85**, 3457–3465.
187. Messmann, R. A., Vitetta, E. S., Headlee, D., Senderowicz, A. M., Figg, W. D., Schindler, J., Michiel, D. F., Creekmore, S., Steinberg, S. M., Kohler, D., Jaffe, E. S., Stetler-Stevenson, M., Chen, H., Ghetie, V., Sausville, E. A. (2000) A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell Lymphoma. *Clin. Cancer Res.* **6**, 1302–1313.
188. Shen, G. L., Li, J. L., Ghetie, M. A., May, R. D., Till, M., Brown, A. N., Relf, M., Knowles, P., Uhr, J. W. (1988) Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the *in vivo* therapy of human B-cell leukemias and lymphomas. *Int. J. Cancer* **42**, 792–797.
189. Vitetta, E. S., Stone, M., Amlot, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J., Thorpe, P. E. (1991) Phase I Immunotoxin Trial in Patients with B-Cell Lymphoma. *Cancer Res.* **51**, 4052–4058.
190. Engert, A., Martin, G., Amlot, P., Wijdenes, J., Diehl, V., Thorpe, P. (1991) Immunotoxins constructed with CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent antitumor effects against human Hodgkin cells *in vitro* and solid Hodgkin tumors in mice. *Int. J. Cancer* **49**, 450–456.
191. Engert, A., Diehl, V., Schnell, R., Radszuhn, A., Hatwig, M. T., Drillich, S., Schön, G., Bohlen, H., Tesch, H., Hansmann, M. L., Barth, S., Schindler, J., Ghetie, V., Uhr, J., Vitetta, E. (1997) A phase I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. *Blood* **89**, 403–410.
192. Schnell, R., Vitetta, E., Schindler, J., Barth, S., Winkler, U., Borchmann, P., Hansmann, M. L., Diehl, V., Ghetie, V., Engert, A. (1998) Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. *Leuk. Lymphoma* **30**, 525–537.
193. Schnell, R., Vitetta, E., Schindler, J., Borchmann, P., Barth, S., Ghetie, V., Hell, K., Drillich, S., Diehl, V., Engert, A. (2000) Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. *Leukemia* **14**, 129–135.
194. Schnell, R., Staak, O., Borchmann, P., Schwartz, C., Matthey, B., Hansen, H., Schindler, J., Ghetie, V., Vitetta, E. S., Diehl, V., Engert, A. (2002) A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4. dgA) in patients with refractory CD30⁺ Hodgkin's and non-Hodgkin's lymphoma. *Clin. Cancer Res.* **8**, 1779–1786.
195. Wels, W., Harwerth, I. M., Mueller, M., Groner, B., Hynes, N. E. (1992) Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. *Cancer Res.* **52**, 6310–6317.
196. von Minckwitz, G., Harder, S., Hövelmann, S., Jäger, E., Al-Batran, S. E., Loibl, S., Atmaca, A., Cimpoiu, C., Neumann, A., Abera, A., Knuth, A., Kaufmann, M., Jäger, D., Maurer, A. B., Wels, W. S. (2005) Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. *Breast Cancer Res.* **7**, 617–626.
197. Friedman, P. N., McAndrew, S. J., Gawlak, S. L., Chace, D., Trail, P. A., Brown, J. P., Siegall, C. B. (1993) BR96 sFv-PE40, a Potent Single-Chain Immunotoxin That Selectively Kills Carcinoma Cells. *Cancer Res.* **53**, 334–339.
198. Posey, J. A., Khazaeli, M. B., Bookman, M. A., Nowrouzi, A., Grizzle, W. E., Thornton, J., Carey, D. E., Lorenz, J. M., Sing, A. P., Siegall, C. B., LoBuglio, A. F., Saleh, M. N. (2002) A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. *Clin. Cancer Res.* **8**, 3092–3099.
199. Chowdhury, P. S., Viner, J. L., Beers, R., Pastan, I. (1998) Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. *Proc. Natl. Acad. Sci. USA* **95**, 669–674.
200. Chowdhury, P. S., Pastan, I. (1999) Improving antibody affinity by mimicking somatic hypermutations *in vitro*. *Nat. Biotechnol.* **17**, 568–572.
201. Hassan, R., Bullock, S., Premkumar, A., Kreitman, R. J., Kindler, H., Willingham, M. C., Pastan, I. (2007) Phase I study of SSIP, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. *Clin. Cancer Res.* **13**, 5144–5149.
202. Kreitman, R. J., Hassan, R., FitzGerald, D. J., Pastan, I. (2009) Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SSIP. *Clin. Cancer Res.* **15**, 5274–5279.
203. Laurent, G., Pris, J., Farcet, J. P., Caravon, P., Casellas, P., Poncelet, P., Jansen, F. K. (1986) Effects of Therapy With T101 Ricin A-Chain Immunotoxin in Two Leukemia Patients. *Blood* **67**, 1680–1687.
204. Hertler, A. A., Schlossman, D. M., Borowitz, M. J., Laurent, G., Jansen, F. K., Schmidt, C., Frankel, A. E. (1988) A Phase I study of T101-ricin A

- chain immunotoxin in refractory chronic lymphocytic leukaemia. *J. Biol. Response Mod.* **7**, 97.
205. Greenfield, L., Johnson, V. G., Youle, R. J. (1987) Mutations in Diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. *Science* **238**, 536–539.
 206. Johnson, V. G., Wrobel, C., Wilson, D., Zovickian, J., Greenfield, L., Oldfield, E. H., Youle, R. (1989) Improved Tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. *J. Neurosurg.* **70**, 240–248.
 207. Laske, D. W., Youle, R. J., Oldfield, E. H. (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. *Nat. Med.* **3**, 1362–1368.
 208. Weaver, M., Laske, D. W. (2003) Transferrin receptor ligand-targeted toxin conjugate (TF-CRM107) for therapy of malignant gliomas. *J. Neurooncol.* **65**, 3–13.
 209. Siegall, C. B., Chaudhary, V. K., Fitzgerald, D. J., Pastan, I. (1989) Functional Analysis of Domains 11, 1b, and 111 of *Pseudomonas* Exotoxin. *J. Biol. Chem.* **264**, 14256–14261.
 210. Goldberg, M. R., Heimbrook, D. C., Russo, P., Sarosdy, M. F., Greenberg, R. E., Giantonio, B. J., Linehan, W. M., Walther, M., Fisher, H. A., Messing, E. (1995) Phase I Clinical Study of the Recombinant Oncotoxin TP40 in Superficial Bladder Cancer. *Clin. Cancer Res.* **1**, 57–61.
 211. Kreitman, R. J., Siegall, C. B., Chaudhary, V. K., Fitzgerald, D. J., Pastan, I. (1992) Properties of Chimeric Toxins with Two Recognition Domains: Interleukin 6 and Transforming Growth Factor α at Different Locations in *Pseudomonas* Exotoxin. *Bioconjug. Chem.* **3**, 63–68.
 212. Philips, P. C., Levow, C., Catterall, M., Colvin, O. M., Pastan, I., Brem, H. (1994) Transforming growth factor- α -*Pseudomonas* exotoxin fusion protein (TGF- α -PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. *Cancer Res.* **54**, 1008–1015.
 213. Sampson, J. H., Akabani, G., Archer, G. E., Bigner, D. D., Berger, M. S., Friedman, A. H., Friedman, H. S., Herndon II, J. E., Kunwar, S., Marcus, S., McLendon, R. E., Paolino, A., Penne, K., Provenzale, J., Quinn, J., Reardon, D. A., Rich, J., Stenzel, T., Tourt-Uhlig, S., Wikstrand, C., Wong, T., Williams, R., Yuan, F., Zalutsky, M. R., Pastan, I. (2003) Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)- α and a mutated form of the *Pseudomonas* exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. *J. Neurooncol.* **65**, 27–35.
 214. Weber, F. Preliminary results of a phase II study of TP-38 immunotoxin delivered via convection-enhanced delivery to patients with recurrent glioblastoma multiforme: report of the TP-38 study group. Meeting abstract, Ann Meeting German Soc Neurosurgery, <http://www.egms.de/en/meetings/dgnc2005/05dgnc0094.shtml>.
 215. Embleton, M. J., Byers, V. S., Lee, H. M., Scannon, P., Blackhall, N. W., Baldwin, R. W. (1986) Sensitivity and Selectivity of Ricin Toxin A Chain-Monoclonal Antibody 791T/36 Conjugates against Human Tumor Cell Lines. *Cancer Res.* **46**, 5524–5528.
 216. Byers, V. S., Rodvien, R., Grant, K., Durrant, L. G., Hudson, K. H., Baldwin, R. W., Scannon, P. J. (1989) Phase I study of monoclonal antibody ricin A chain immunotoxin XOMAZYME-791 in patients with metastatic colon cancer. *Cancer Res.* **49**, 6153.
 217. Spitzer, L. E., del Rio, M., Khenigian, A., Wedel, N. I., Brophy, N. A., Miller, L. L., Harkonen, W. S., Rosendorf, L. L., Lee, H. M., Mischak, R. P., Kawahata, R. P., Stoudemire, J. B., Fradkin, L. B., Bautista, E. E., Scannon, P. J. (1987) Therapy of patients with malignant melanoma using a monoclonal anti-melanoma antibody-ricin A chain immunotoxin. *Cancer Res.* **47**, 1717.
 218. Oratz, R., Speyer, J. L., Wernz, J. C., Hochster, H., Meyers, M., Mischak, R., Spitzer, L. E. (1990) Antimelanoma monoclonal antibody-ricin-A chain immunotoxin conjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a Phase II trial. *J. Biol. Response Mod.* **9**, 345–354.
 219. Selvaggi, K., Saria, E. A., Schwartz, R., Vlock, D. R., Ackerman, S., Wedel, N., Kirkwood, J. M., Jones, H., Ernstoff, M. S. (1993) Phase I/II study of murine monoclonal antibody-ricin A chain (Xomazyme-Mel) immunotoxin conjugate plus cyclosporine A in patients with metastatic melanoma. *J. Immunother.* **13**, 201–207.
 220. Matsushita, S., Koito, A., Maeda, Y., Hattori, T., Takatsuki, K. (1990) Selective killing of HIV-infected cells by anti-gp 120 immunotoxins. *AIDS Res. Hum. Retroviruses* **6**, 193–203.
 221. Bera, T. K., Kennedy, P. E., Berger, E. A., Barbas III, C. F., Pastan, I. (1998) Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. *Mol. Med.* **4**, 384–391.
 222. Mareeva, T., Wanjalla, C., Schnell, M. J., Sykulev, Y. (2010) A novel composite immunotoxin that suppresses rabies virus production by the infected cells. *J. Immunol. Methods* **353**, 78–86.
 223. Pincus, S. H., Cole, R. L., Hersh, E. M., Lake, D., Masuho, Y., Durda, P. J., McClure, J. (1991) In vitro efficacy of anti HIV immunotoxins targeted by various antibodies to the envelope protein. *J. Immunol.* **146**, 4315–4324.
 224. Pincus, S. H., Wehrly, K., Chesebro, B. (1989) Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. *J. Immunol.* **142**, 3070–3075.
 225. McCoig, C., Van Dyke, G., Chou, C. S., Picker, L. J., Ramilo, O., Vitetta, E. S. (1999) An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. *Proc. Natl. Acad. Sci. USA* **96**, 11482–11485.
 226. Till, M. A., Zolla-Pazner, S., Gorny, M. K., Pattons, J. S., Uhr, J. W., Vitetta, E. S. (1989) Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. *Proc. Natl. Acad. Sci. USA* **86**, 1987–1991.
 227. Kim, Y., Fung, M. S. C., Sun, N., Sun, C. R. Y., Chang, N. T., Chang, T. W. (1990) Immunoconjugates that neutralize HIV virions kill T cells infected with diverse strains of HIV-1. *J. Immunol.* **144**, 1257–1262.
 228. Tazzari, P. L., de Toter, D., Bolognesi, A., Testoni, N., Pileri, S., Roncella, S., Reato, R., Stein, H., Gobbi, M., Stürpe, F. (1999) An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30⁺ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins. *Haematologica* **84**, 988–995.
 229. Chaudhary, V. K., Mizukami, T., Fuerst, T. R., Fitzgerald, D. J., Moss, B., Pastan, I., Berger, E. A. (1988) Selective killing of HIV-infected cells by recombinant human CD4-pseudomonas exotoxin hybrid protein. *Nature* **335**, 369–372.
 230. Davey, R. T., Jr., Boenning, C. M., Herpin, B. R., Batts, D. H., Metcalf, J. A., Wathen, L., Cox, S. R., Polis, M. A., Kovacs, J. A., Falloon, J., Walker, R. E., Salzman, N., Masur, H., Lane, C. (1994) Use of recombinant soluble CD4 pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with immunodeficiency virus. *J. Infect. Dis.* **170**, 1180–1188.
 231. Aulio, P., Alcamil, J., Popoff, M. R., Klatzmann, D. R., Murphy, J. R., Boquet, P. (1992) A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV. *EMBO J.* **11**, 575–583.
 232. Finberg, R. W., Wahl, S. M., Allen, J. B., Soman, G., Strom, T. B., Murphy, J. R., Nichols, J. C. (1991) Selective elimination of HIV-1 infected cells with an interleukin-2 receptor-specific cytotoxin. *Science* **252**, 1703–1705.
 233. Zhang, L., Waters, C., Nichols, J., Crumpacker, C. (1992) Inhibition of HIV-1 RNA production by the diphtheria toxin related IL-2 fusion proteins DAB486IL-2 and DAB389IL-2. *J. Acquir. Immune Defic. Syndr.* **5**, 1181–1187.
 234. Pincus, S. H., McClure, J. (1993) Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus. *Proc. Natl. Acad. Sci. USA* **90**, 332–336.
 235. Tedder, T. F., Goldmacher, V. S., Lambert, J. M., Schlossman, S. F. (1986) Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system. *J. Immunol.* **137**, 1387–1391.
 236. Barnett, B. B., Burns, N. J., Park, K. J., Dawson, M. I., Kende, M., Sidwell, R. W. (1991) Antiviral immunotoxins: antibody-mediated delivery of gelonin inhibits Pichinde virus replication in vitro. *Antiviral Res.* **15**, 125–138.
 237. Zarling, J. M., Moran, P. A., Haffar, O., Sias, J., Richman, D. D., Spina, C. A., Myers, D. E., Kuebelbeck, V., Ledbetter, J. A., Uckun, F. M. (1990) Inhibition of HIV-replication by pokeweed antiviral protein targeted to CD4⁺ cells by monoclonal antibodies. *Nature* **347**, 92–95.
 238. Till, M. A., Ghetie, V., Gregory, T., Patzer, E. J., Porter, J. P., Uhr, J. W., Capon, D. J., Vitetta, E. S. (1988) HIV-infected cells are killed by rCD4 ricin A chain. *Science* **242**, 1166–1168.
 239. Engert, A., Martin, G., Amlot, P., Wijdenes, J., Diehl, V., Thorpe, P. (1991) Immunotoxins constructed with CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent antitumor effects against human Hodgkin cells in vitro and solid Hodgkin tumors in mice. *Int. J. Cancer* **49**, 450–456.
 240. Bell, K. D., Ramilo, T., Vitetta, E. S. (1993) Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type I human immunodeficiency virus. *Proc. Natl. Acad. Sci. USA* **90**, 1411–1415.
 241. Youle, R. J., Uckun, F. M., Vallera, D. A., Colombatti, M. (1986) Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen. *J. Immunol.* **136**, 93–98.